Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials

More on GLP-1 receptor agonists

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026

• GLP-1 receptor agonists link to lower stroke and Alzheimer risk

  Neurology Genetics · 4 Oct 2026